ClinicalTrials.gg
RecruitingNCT05675527Updated Oct 9, 2026

PRP for Glenohumeral Osteoarthritis

A Phase 4 interventional study of Low-dose PRP and High-dose PRP in Shoulder Osteoarthritis, sponsored by Hospital for Special Surgery, New York. Recruiting at 1 site in United States. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-10-09.

Sponsored by Hospital for Special Surgery, New York · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Started May 2023; still recruiting 3 years 6 months later.
Updated Oct 9, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
135
Allocation
Randomized
Ages
18 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 28 studies testing platelet rich plasma in Osteoarthritis — 6 open to participants now, 6 under way, 1 of them phase 3. platelet rich plasma · Osteoarthritis.

Planned enrollment
9th of 28
135 · median 70
Started
2023
with 2 others
Phase 4
7 of 28
2 open now
Registered
21st of 28
by date
Lead sponsor
2 of 28
Hospital for Special Surgery, New York

Among the 28 studies testing platelet rich plasma in Osteoarthritis, this one is the 9th largest by planned enrollment, is one of 3 that started in 2023, is one of 7 in phase 4, and was the 21st registered.

Osteoarthritis

2,978 studies on the registry are indexed under Osteoarthritis; 438 are open to participants now.

Browse Osteoarthritis studies →

Open to participants now

6 of the 28 studies testing platelet rich plasma in Osteoarthritis are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

About platelet rich plasma

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 285 Osteoarthritis studies recruiting now, 158 (55%) set no upper age limit and 70 (25%) stop at 75 or younger; 22 take children under 18; 31 take healthy volunteers.

This study: 18 Years to 100 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies testing platelet rich plasma in Osteoarthritis, or all of them as a file.
02

Study summary

The glenohumeral joint is the third most common large joint to be affected by OA. Conservative treatments include physical activity, corticosteroid injections, and medications. PRP is an emerging treatment that has shown efficacy in different musculoskeletal conditions. The use of PRP for glenohumeral OA has been described sparingly in the literature but has shown efficacy in a couple studies and case reports. However, all of the previous studies investigating PRP for glenohumeral OA have focused on low-dose PRP preparations (\~3X), and none have compared PRP treatment to saline treatment. This study aims to compare outcomes following single injections of low-dose PRP, high-dose PRP, or saline in patients with glenohumeral osteoarthritis.

03

Conditions studied

  • Shoulder Osteoarthritis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18-100 years old
  • Average NRS pain greater than or equal to 5/10 as a direct result of glenohumeral osteoarthritis (any severity: mild, moderate, or severe) and/or chondral lesion or loss
  • At least 3 months of pain after onset of symptoms that has failed conservative treatments, including physical therapy
  • MRI of the affected joint
  • Transient relief of symptoms after a diagnostic intra-articular injection into the joint
  • Email address or network access

Exclusion criteria

Exclusion Criteria:

  • Inability to hold non-steroidal anti-inflammatory drugs for 2 weeks prior and 1 month after the injection
  • Prior -rich plasma injection
  • injection within 3 months of the initial injection
  • Hyaluronic acid within 6 months of the initial injection
  • Involved in workers' compensation or active litigation involving the affected joint
  • History of Plavix use
  • Known uncontrolled systemic illness (uncontrolled diabetes, , vasculitis, /autoinflammatory disease)
  • Presence of acute fractures or gross mechanical deformities
  • Concurrent "uncontrolled" cervical disorders
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Outcomes assessor)
Enrollment
135 participants (estimated)

Study arms

  • Experimental
    Low-dose PRP

    Patients will receive a single injection of 6 ml low-dose platelet-rich plasma (PRP) into the glenohumeral joint. Low-dose is defined as a platelet yield of 3X (i.e., 3-fold increase in platelets in PRP compared to whole blood).

    Biological: Low-dose PRP

  • Experimental
    High-dose PRP

    Patients will receive a single injection of 6 ml high-dose platelet-rich plasma (PRP) into the glenohumeral joint. High-dose is defined as a platelet yield of 12X (i.e., 12-fold increase in platelets in PRP compared to whole blood).

    Biological: High-dose PRP

  • Placebo comparator
    Saline control

    Patients will receive a single injection of 6 ml saline into the glenohumeral joint.

    Other: Saline

Interventions

06

What researchers measure

Primary outcomes

  1. American Shoulder and Elbow Surgeons (ASES) Shoulder Score

    The ASES measures pain and function in activities of daily living related to the shoulder. On a 100-point scale, a higher score represents less pain/higher function.

    Time frame: 3 months post-injection

Secondary outcomes

  1. Average numerical rating scale (NRS) pain score

    Average NRS pain during the past week. This is on a scale of 0-10, with 0 representing no pain and 10 representing the worst pain possible.

    Time frame: Up to 12 months post-injection

  2. Patient-Reported Outcomes Measurement Information System (PROMIS)-10 Global Health measure

    The PROMIS-10 assesses physical health and mental health. A higher score represents better physical health and mental health.

    Time frame: Up to 12 months post-injection

  3. PROMIS-Upper Extremity computer adaptive test (CAT)

    The PROMIS-Upper Extremity CAT measures upper extremity (shoulder) function. A higher scores represents better function.

    Time frame: Up to 12 months post-injection

  4. Medication use

    Patients will be asked if they are using any of the following medications: non-steroidal anti-inflammatory drugs, opioids, selective serotonin reuptake inhibitors, or neuropathic medications.

    Time frame: Up to 12 months post-injection

  5. PROMIS Sleep Disturbance

    The PROMIS sleep disturbance measures sleep impairment/disturbance. A higher score represents more sleep disturbance (e.g., worse sleep quality).

    Time frame: Up to 12 months post-injection

  6. Patient satisfaction

    Patient satisfaction is assessed on a 0-10 scale, with 0 meaning "not satisfied at all" and 10 meaning "very satisfied".

    Time frame: Up to 12 months post-injection

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2023 (actual). Primary completion is estimated for Jun 2028, 60 months after the start.

Of 54 non-industry phase 4 interventional studies under Osteoarthritis, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 60. This study's planned 60 months is above that.

Counting every sponsor, half of 63 studies reached it within 28 months; a quarter within 11 and three quarters within 60.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 9, 2026: primary completion Sep 2026 → Jun 2028 and completion Sep 2026 → Jun 2029.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Dec 28, 2022
First posted
Jan 9, 2023
StartActual
May 2, 2023
Primary completionEst.
Jun 1, 2028was Sep 2026
CompletionEst.
Jun 1, 2029was Sep 2026
Last update
Oct 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Sep 1, 2026→Jun 1, 2028
Oct 9, 2026
Study completion
Sep 1, 2026→Jun 1, 2029
Oct 9, 2026
Show all 1 update
  1. Oct 9, 2026
    Primary completion Sep 1, 2026→Jun 1, 2028
    Study completion Sep 1, 2026→Jun 1, 2029
    + 2 other changes: verification date and oversight details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT05675527
Responsible party
Sponsor
First posted
Jan 9, 2023
Start date
May 2, 2023
Primary completion
Jun 1, 2028 (estimated)
Completion
Jun 1, 2029 (estimated)
Last update
Oct 9, 2026

Study contacts

Jonathan Kirschner, MD
Contact
kirschnerj@hss.edu
646-714-6327
Jennifer Cheng
Contact
chengj@hss.edu
646-714-6870

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Platelet rich plasma

Start the discussion